Apogee Therapeutics reported phase II maintenance data for zumilokibart (APG‑777) showing durable EASI‑75 responses with dosing every three to six months, results the company presented and STAT summarized. The trial readouts demonstrated sustained skin and itch improvement at extended dosing intervals, positioning the antibody as a potential competitor to existing IL‑13/IL‑4 pathway biologics by offering far less frequent injections. Management and analysts have framed the data as clinically meaningful and commercially significant if replicated in larger trials; Apogee plans to advance development with confirmatory studies.